<DOC>
	<DOCNO>NCT02620020</DOCNO>
	<brief_summary>The main objective trial evaluate efficacy fasinumab compare placebo measure change baseline average daily Low Back Pain Intensity ( LBPI ) Numerical Rating Scale ( NRS ) . Secondary objective study evaluate efficacy fasinumab compare placebo measure : - Change baseline Roland Morris disability questionnaire ( RMDQ ) total score - Change baseline Patient Global Assessment ( PGA ) Low Back Pain ( LBP ) score - Change baseline average daily LBPI NRS score</brief_summary>
	<brief_title>A Study Determine Efficacy Safety Fasinumab Treatment Adults With Chronic Low Back Pain</brief_title>
	<detailed_description />
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<criteria>Key 1 . Male female ≥35 year age screen visit 2 . Clinical diagnosis chronic moderate severe LBP ( nonradiculopathic ) ≥3 month 3 . History regular analgesic medication 4 . History inadequate pain relief intolerance analgesic use chronic LBP 5 . Willing discontinue current pain medication Key 1 . History lumbosacral radiculopathy within past 2 year 2 . Evidence baseline lumbar spine magnetic resonance image potentially confound condition 3 . Recent use longer act pain medication 4 . Evidence destructive arthropathy 5 . Other medical condition may interfere participation accurate assessment trial</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>